Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
In Ankleshwar, feisty MSMEs that survived the Chinese onslaught say that the fight against red tapism is harder
By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next
A strong product pipeline and receding US FDA threat could well turn the tide in favour of the beleaguered pharma players
Lupin is betting on its specialty drugs business to counter the pricing pressures in the US generics market
His bet on Natco Pharma’s differentiated product portfolio paid off while Monnet Ispat taught him to be wary of over-ambitious entrepreneurs
Why Star paid top dollar for India's premier domestic tourney
The pharma index has hugely underperformed the Sensex in CY17 owing to regulatory overhang and FDA issues
Vishnukant Bhutada’s big bet on oncology has catapulted Shilpa Medicare into the global generics space
Promoter Desh Bandhu Gupta buys 88,000 shares from the market as Lupin trades near its 52-week low
The domestic pharma industry, which is already battling the US FDA, has now to contend with regulatory challenges at home
Even as it battles the US FDA, the industry has been caught off-guard by policy changes back home
Leading finance minds on how to navigate the funding environment in 2017
Leading experts crystal gaze at the inaugural Outlook Business Brunch Roundtable
Promoter Desh Bandhu Gupta is increasing his holding in Lupin
Mankind Pharma made it big in small towns, but can its magic help it conquer the bigger markets?
After a dream run, Sun Pharma is grappling with growth and regulatory issues. Can the country’s biggest drug maker rediscover its mojo?
The worst year in a decade for the auto sector has cast a shadow on units in Pithampur
Lupin wants to keep bingeing on overseas markets and specialty segments for growth
Kamal K Sharma, managing director of Lupin, lists the 5E principles for promoting leadership in an organisation
Tectonic changes in the US generic drugs market is causing huge shifts in Indian pharma’s strategies as well